Đang chuẩn bị liên kết để tải về tài liệu:
A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease that lack of effective therapeutic drugs. K-001 is an oral antitumor drug made from active ingredients of marine microorganisms. The current study aimed to evaluate safety and antitumor activity of K-001 in patients with advanced PDAC. |

TÀI LIỆU LIÊN QUAN

Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: Study protocol

A prospective phase I study of hypofractionated neoadjuvant radiotherapy for locally advanced gastric cancer

BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: A first-inhuman phase-I study

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies

A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma

Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease smallcell lung cancer (LD-SCLC): TORG 0604

Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses

Optimal biological dose: A systematic review in cancer phase I clinical trials

Phase I clinical study of oral olaparib in pediatric patients with refractory solid tumors: Study protocol

A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer